Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 1;29(3):392-396.
doi: 10.1093/eurpub/cky209.

A microsimulation model projecting the health care costs for resistance to antibacterial drugs in Sweden

Sofie Larsson  1   2 , Magdalena Prioux  1 , Tobias Fasth  1 , Anders Ternhag  1   3 , Johan Struwe  1 , Ulrica Dohnhammar  1 , Lisa Brouwers  1
Affiliations

A microsimulation model projecting the health care costs for resistance to antibacterial drugs in Sweden

Sofie Larsson et al. Eur J Public Health. .

Abstract

Background: Previous studies have shown that increasing antibacterial resistance (ABR) globally will cause extensive morbidity, deaths and escalated health care costs.

Methods: To project economic consequences of resistance to antibacterial drugs for the Swedish health care sector, we used an individual-based microsimulation model, SESIM. Health care consumption was represented as increased numbers of hospital days, outpatient visits and contact tracing for individuals getting clinical infections or becoming asymptomatic carriers. The risk of contracting a resistant bacterium was calculated using the incidence of mandatorily notifiable ABR in Sweden.

Results: We estimate accumulated additional health care costs attributable to notifiable ABR from 2018 until 2030 to EUR 406 million and EUR 1, 503 million until 2050. Until 2030 the largest proportion, more than EUR 247 million (EUR 958 million until 2050), was due to ESBL, followed by methicillin resistant Staphylococcus aureus, carbapenemase-producing Enterobacteriaceae, vancomycin-resistant Enterococci and penicillin non-susceptible Pneumococci which incurred costs of EUR 128 million (EUR 453 million, 2050), EUR 15 million (EUR 58 million, 2050), EUR 13 million (EUR 28 million, 2050) and EUR 2 million (EUR 6 million, 2050), respectively.

Conclusions: Projections concerning the future costs of ABR can be used to guide priorities and distribution of limited health care resources. Our estimates imply that costs in Sweden will have doubled by 2030 and increased more than 4-fold by 2050 if present trends continue and infection control practices remain unchanged. Still, indirect societal costs and costs for non-notifiable resistance remain to be added.

PubMed Disclaimer

References

    1. The Sixty-eight World Health Assembly (WHA). Global action plan on antimicrobial resistance, Title no. WHA68.7, 2015. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R7-en.pdf.
    1. Cosgrove SE, Sakoulas G, Perencevich EN, et al.Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53–9. - PubMed
    1. Smith R, Coast J. The true cost of antimicrobial resistance. BMJ 2013;346:f1493. - PubMed
    1. Smith RCJ. The Economic Burden of Antimicrobial Resistance: Why It Is More Serious than Current Studies Suggest. Technical Report. London, 2012.
    1. Roberts RR, Hota B, Ahmad I, et al.Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49:1175–84. - PubMed